Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03624062 · ClinicalTrials.gov registry record · Phase 1
MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT03624062 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 21 participants.
The verdict
NCT03624062, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The study is a randomized, double-masked, placebo-controlled, Phase 1 dose-escalation clinical trial. The objective of the trial is to determine if IBC adjuvanted with MAS-1 is safe and will favor tolerogenic pathways to restore immunologic balance and reverse type 1 diabetes (T1D) autoimmunity.
Interventions
- DRUG MAS-1 adjuvanted Insulin B-chain
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2020-08-31 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03624062
The ClinicalTrials.gov registry entry for NCT03624062 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MAS-1 adjuvanted Insulin B-chain is the first listed.
NCT03624062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03624062 about?
NCT03624062 is a clinical study titled "MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes". The study is a randomized, double-masked, placebo-controlled, Phase 1 dose-escalation clinical trial. The objective of the trial is to determine if IBC adjuvanted with MAS-1 is safe and will favor tolerogenic pathways to restore immunologic balance and reverse type 1 diabetes (T1D) autoimmunity.
What is the current status of trial NCT03624062?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2020-08-31. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT03624062?
The interventions under investigation include: MAS-1 adjuvanted Insulin B-chain (DRUG).
Who is sponsoring clinical trial NCT03624062?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.